Breaking News, Collaborations & Alliances

Agios Exercises Option in Celgene Alliance

Retains U.S. development and commercial rights to IDH1 program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Agios Pharmaceuticals, Inc. has elected to retain U.S. development and commercial rights to the isocitrate dehydrogenase 1 (IDH1) program, including the clinical candidate AG-120, under its global collaboration with Celgene Corp. in the field of cancer metabolism.   Agios will lead development and commercialization activities for AG-120 in the U.S., and Celgene retains the option to lead development and commercialization for AG-120 in the rest of the world. AG-120 is an orally available, selecti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters